These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33903854)

  • 1. Convalescent plasma therapy - a silver lining for COVID-19 management?
    Saha S; Kadam S
    Hematol Transfus Cell Ther; 2021; 43(2):201-211. PubMed ID: 33903854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
    Wooding DJ; Bach H
    Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outpatient regimens to reduce COVID-19 hospitalisations: a systematic review and meta-analysis of randomized controlled trials.
    Sullivan DJ; Focosi D; Hanley DF; Cruciani M; Franchini M; Ou J; Casadevall A; Paneth N
    medRxiv; 2023 Jun; ():. PubMed ID: 35665014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Chai KL; Valk SJ; Piechotta V; Kimber C; Monsef I; Doree C; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Oct; 10():CD013600. PubMed ID: 33044747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review.
    Kandula UR; Tuji TS; Gudeta DB; Bulbula KL; Mohammad AA; Wari KD; Abbas A
    J Blood Med; 2023; 14():159-187. PubMed ID: 36855559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V; Iannizzi C; Chai KL; Valk SJ; Kimber C; Dorando E; Monsef I; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013600. PubMed ID: 34013969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Convalescent plasma for people with COVID-19: a living systematic review.
    Iannizzi C; Chai KL; Piechotta V; Valk SJ; Kimber C; Monsef I; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Jindal A; Cryns N; Estcourt LJ; Kreuzberger N; Skoetz N
    Cochrane Database Syst Rev; 2023 May; 5(5):CD013600. PubMed ID: 37162745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Convalescent plasma for people with COVID-19: a living systematic review.
    Iannizzi C; Chai KL; Piechotta V; Valk SJ; Kimber C; Monsef I; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Jindal A; Cryns N; Estcourt LJ; Kreuzberger N; Skoetz N
    Cochrane Database Syst Rev; 2023 Feb; 2(2):CD013600. PubMed ID: 36734509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deployment of convalescent plasma for the prevention and treatment of COVID-19.
    Bloch EM; Shoham S; Casadevall A; Sachais BS; Shaz B; Winters JL; van Buskirk C; Grossman BJ; Joyner M; Henderson JP; Pekosz A; Lau B; Wesolowski A; Katz L; Shan H; Auwaerter PG; Thomas D; Sullivan DJ; Paneth N; Gehrie E; Spitalnik S; Hod EA; Pollack L; Nicholson WT; Pirofski LA; Bailey JA; Tobian AA
    J Clin Invest; 2020 Jun; 130(6):2757-2765. PubMed ID: 32254064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals.
    Beaudoin-Bussières G; Laumaea A; Anand SP; Prévost J; Gasser R; Goyette G; Medjahed H; Perreault J; Tremblay T; Lewin A; Gokool L; Morrisseau C; Bégin P; Tremblay C; Martel-Laferrière V; Kaufmann DE; Richard J; Bazin R; Finzi A
    mBio; 2020 Oct; 11(5):. PubMed ID: 33067385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Successful administration of convalescent plasma in critically ill COVID-19 patients in Hungary: the first two cases].
    Bobek I; Gopcsa L; Réti M; Bekő G; Hancz L; Lakatos B; Molnár E; Nagy S; Reményi P; Sebestyén G; Sinkó J; Szlávik J; Szolnoky M; Vályi-Nagy I
    Orv Hetil; 2020 Jul; 161(27):1111-1121. PubMed ID: 32564002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convalescent plasma treatment for COVID-19: Tempering expectations with the influenza experience.
    Subbarao K; Mordant F; Rudraraju R
    Eur J Immunol; 2020 Oct; 50(10):1447-1453. PubMed ID: 32886952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.
    Kumar P; Sah AK; Tripathi G; Kashyap A; Tripathi A; Rao R; Mishra PC; Mallick K; Husain A; Kashyap MK
    Mol Cell Biochem; 2021 Feb; 476(2):553-574. PubMed ID: 33029696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.